Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR
monoclonal antibody（SCT200）in patients with Recurrent and/or Metastatic Head and Neck
Squamous Cell Carcinoma after failure of platinum-based therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sinocelltech Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences